BI-SBPH@EC2704A

China Biopharma: Subsidiary's Innovative Drug Naldemedine Approved by NMPA for Launch

China Biopharm: Subsidiary's IDH1 Inhibitor TQB3454 Included in Priority Review

China Biopharma Subsidiary Hepzha Announces Phase I Clinical Data for Innovative Drug Kylo-0603

China Biopharmaceutical announces positive M701 trial results and drug application acceptance

China Biopharmaceutical's Jointly Promoted Drug Shenghetu Approved for First-Line NSCLC Treatment

China Biopharma's Zongertinib Approved by NMPA as First-Line Treatment for HER2-Mutated NSCLC

China Biopharma spends 10 million HKD to repurchase 1.89 million shares on May 18

China Biopharma spends 10.0269 million HKD to repurchase 1.87 million shares

China Biopharmaceutical Announces Preclinical Results of Obesity Treatment Candidate TQF6422

China Bio-Pharmaceuticals repurchased 1.78 million shares

China Biopharmaceutical bought back 1.81 million shares for HKD10.0149 million

China BioPharmaceuticals repurchasing 1.81 million shares

China Biologic Pharmaceutical's subsidiary Chengdu Tianqing Submits New Drug Application

China Biopharmaceutical repurchased 1.86 million shares at HKD5.38-5.44 per share and cancelled

China Biopharmaceutical's New Drug M701 Accepted by the National Medical Products Administration

China Biologic Products Recruits First Patient for LM-108 Phase III Clinical Trial

Chang Xiangling Increased Holdings in China Bio-Pharmaceuticals by 1 Million Shares

China Biologic Pharmaceutical Receives NMPA Approval to Produce Culmerciclib Capsules for Breast Cancer Treatment

China Bio-Pharmaceutical Repurchased 1.87 Million Shares

JOLIMARK

TIMES UNI GP

APEX ACE HLDG

VPOWER GROUP

GW TIANDI

FUJING HOLDINGS

TEAMWAY INTL GP

SFSY NEW MAT

FDB HOLDINGS

KEEN OCEAN

SBIO

GSK plc announced positive Phase III trial results for its hepatitis B treatment, bepirovirsen, with 19% of patients achieving a functional cure compared to 0% in the placebo group. In patients with lower viral activity, the cure rate rose to 26%. Additionally, 23% of treated patients maintained viral suppression at week 72 post-therapy. The trials involved over 1,800 participants and showed a safety profile similar to previous studies. Bepirovirsen is under priority review by the FDA, with regulatory decisions expected by Q3 2026.

nasdaq

GlaxoSmithKline plc

ALPS Medical Breakthrough

VG Health

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

iShares Biotechnology ETF

Invesco Nasdaq Biotechnology ETF

iShares US Pharma

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

Health Care Select Sector SPDR

Ark Genomic Revolution ETF

Nasdaq

GSK plc Sponsored ADR

GSK Says Bepirovirsen Achieves Phase III Functional Cure Goal In Chronic Hepatitis B

01177

Sino Biopharmaceutical's subsidiary, Chia Tai Tianqing, presented promising preclinical data for TQF6422, a monoclonal antibody aimed at obesity treatment, at the European Congress on Obesity 2026. The drug demonstrated significant fat reduction and muscle preservation in animal models, outperforming competitors. With a favorable safety profile and plans for clinical trials, TQF6422 is part of a broader weight-loss pipeline, including other innovative therapies. Analysts rate Sino Biopharmaceutical (HK:1177) stock as a Buy, with a target price of HK$8.70, reflecting confidence in its growth in the obesity treatment market.

Tip Ranks

SBP GROUP

Sino Biopharm Showcases Promising Obesity Antibody Data and Expands Weight-Loss Pipeline

GSK has partnered with SBP Group to launch bepirovirsen in China, leveraging CTTQ's extensive network of over 5,000 medical centers. GSK will manage regulatory and quality oversight while SBP Group handles distribution and promotional activities. Bepirovirsen, an investigational treatment for chronic hepatitis B, aims to address a significant healthcare issue affecting 75 million people in China. The drug has received priority review and breakthrough designations in multiple countries. GSK's recent acquisition of SiranBio's therapy further supports its expansion into new treatment areas.

Pharmaceutical Business Review

Ionis Pharma

GSK and SBP Group team up to advance bepirovirsen launch in China

512010

560600

516930

G Sachs has raised the target price for SBP GROUPto HKD8.05, maintaining a Buy rating following the company's agreement with GlaxoSmithKline (GSK) for exclusive commercialization rights in China for the hepatitis B drug bepirovirsen. The drug, expected to be approved in 2027, aligns with the treatment needs of China's 75 million chronic hepatitis B patients. G Sachs has increased its earnings forecasts for 2027 and 2028 by 1.1% and 1.7%, respectively, reflecting the anticipated sales contribution from bepirovirsen.

AASTOCKS News

E Fund CSI 300 Health Care ETF

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Guotai SSE STAR Brand Name Drug ETF

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

Penghua SSE STAR Biology and Medicine ETF

Guotai CSI Bio-medicine ETF

ICBCCS SSE STAR Biology and Medicine ETF

Yinhua CSI Innovative Drugs Industry ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Minsheng Royal CSI Biotechnology Theme ETF

Tianhong CNI BIOMEDICINE ETF

China Universal 800 Health Care ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

E Fund Hang Seng SCHK Innovative Drug ETF

China Southern Hang Seng Biotech ETF(QDII)

GF CSI HK Innovative Drugs Industry ETF(QDII)

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Goldman Sachs

GS Hldg R

G Sachs Raises SBP GROUP  TP to HKD8.05, Maintains Buy on Introduction of GSK Hepatitis B Drug

Sino Biopharmaceutical has announced that its subsidiary LaNova Medicines has enrolled the first patient in a Phase III clinical trial for cafelkibart (LM-108), a CCR8 monoclonal antibody, targeting advanced gastric cancer. This trial follows two Breakthrough Therapy Designations in China and aims to position LM-108 as a first-in-class therapy. Early data indicates improved response rates and survival compared to standard treatments. Analysts rate the stock as a Buy with a target price of HK$8.70, reflecting positive market sentiment.

Sino Biopharm Advances First-in-Class CCR8 Antibody Into Phase III Gastric Cancer Trial

Sino Biopharmaceutical (HK:1177) has announced a hybrid annual general meeting scheduled for June 17, 2025, allowing both in-person and online participation. The agenda includes reviewing the 2025 audited results, approving a final dividend, re-electing directors, re-appointing Ernst & Young as auditor, and granting authority to issue up to 20% of the company’s share capital. Analysts rate the stock as a Buy with a target price of HK$8.70. The company focuses on biopharmaceutical and chemical medicines in the healthcare sector, with a market cap of HK$99B.

Sino Biopharm Sets Hybrid AGM, Seeks Fresh Share Issue Mandate

Sino Biopharmaceutical's unit LaNova Medicines presented promising preclinical data on two antibody-drug conjugates, LM-364 and LM-338, at the AACR Annual Meeting 2026. These ADCs target solid tumors, with LM-364 showing strong antitumor activity and a favorable safety profile, progressing towards an IND filing with the U.S. FDA. LM-338 demonstrated high target specificity, indicating potential for future pipeline expansion. Analysts rate Sino Biopharmaceutical (HK:1177) stock as a Buy with a price target of HK$8.70, reflecting confidence in its oncology-focused innovations.

Penghua CSI HK Connect Health Care Composite ETF

Sino Biopharm Unit LaNova Unveils Promising ADC Data at AACR 2026

08037

Sino Biopharmaceutical's subsidiary LaNova Medicines presented promising early clinical data for MK-2010/LM-299, a PD-1/VEGF bispecific cancer drug licensed to Merck. In a Phase 1/2 study with 112 patients, the drug demonstrated a manageable safety profile and notable efficacy signals, particularly in non-small cell lung cancer, with an overall response rate of 55% at 20 mg/kg. This development enhances Sino Biopharmaceutical's position in oncology and underscores the strategic partnership with Merck. Analysts rate the stock as a Buy with a target price of HK$8.70.

CH BIOTECH SER

Bosera Hang Seng Health Care ETF(QDII)

Dacheng CSI All Share Health Care Equipment and Services ETF

Merck

Sino Biopharm Reports Promising Early Data for PD-1/VEGF Bispecific Cancer Drug Licensed to Merck

BI-SBPH@EC2704A(29500.HK)